305.779.4120 info@nicogenpharma.com

Research

Even with the proven harmful effects of tobacco use, more 42 million U.S. adults continue to smoke. With the evolution of NRTs (Nicotine Replacement Therapy) and reduced-risk tobacco, extensive research has been done showing reduced-harm products are a viable option for active smokers and can help reduce overall tobacco related diseases.

Survey of smokers’ reasons for not switching to safer sources of nicotine and their willingness to do so in the future. https://harmreductionjournal.biomedcnreduceentral.com/articles/10.1186/1477-7517-6-14

US smokers’ reactions to a brief trial of oral nicotine products.
https://pdfs.semanticscholar.org/37b2/23b6df375ceb03323f7ac86646ea55062998.pdf

Randomized clinical trial of snus versus medicinal nicotine among smokers interested in product switching.
http://tobaccocontrol.bmj.com/content/tobaccocontrol/early/2015/05/19/tobaccocontrol-2014-052080.full.pdf

https://www.fda.gov/TobaccoProducts/default.htm

http://tobaccoharmreduction.org/faq/nicotine.htm